Type 17 T helper cells - Origins, features and possible roles in rheumatic disease

Nature Reviews Rheumatology

Volumn 5, Issue 6, 2009, Pages 325-331

  Annunziato, Francesco ^a   Cosmi, Lorenzo ^a   Liotta, Francesco ^a   Maggi, Enrico ^a   Romagnani, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; RHEUMATIC DISEASE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; HUMANS; INTERLEUKIN-17; RHEUMATIC DISEASES; T-LYMPHOCYTE SUBSETS;

EID: 68849125507     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.80     Document Type: Review

References (77)

1. Mosmann, T. R., Cherwinski, C., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986).
2. Romagnani, S. Human TH1 and TH2 subsets: doubt no more. Immunol. Today 12, 256-257 (1991).
3. Romagnani, S. The TH1/TH2 paradigm. Immunol. Today 18, 263-266 (1997).
4. Gately, M. K. et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16, 495-521 (1998).
5. Cua, D. J. et al. interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
6. Murphy, C. A. et al. Divergent pro- and antiinflammatory roles for iL-23 and iL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1958 (2003).
7. Yao, Z. et al. Herpesvirus saimiri encodes a new cytokine, iL-17, which binds to a novel cytokine receptor. Immunity 3, 811-821 (1995).
8. Dong, C. regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol. Rev. 226, 80-86 (2008).
9. Bettelli, E. et al. reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 44, 235-238 (2006).
10. H17 lineage. Nature 441, 231-234 (2006).
11. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & stockinger, B. TGF-beta in the context of an inflammatory cytokine milieu supports differentiation of iL-17-producing T cells. Immunity 25, 179-189 (2006).
12. Bettelli, E. et al. reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 44, 235-238 (2006).
13. Huber, M. et al. irF4 is essential for iL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc. Natl Acad. Sci. USA 105, 20846-20851 (2008).
14. Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A. & stockinger, B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206, 43-49 (2009).
15. + T helper cells. Cell 126, 1121-1131 (2006).
16. Yang, X. O. et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors rOrα and rOrγ. Immunity 28, 29-39 (2008).
17. Chen, Z., Laurence, A. & O'shea, J. J. signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol. 19, 400-408 (2007).
18. Ouyang, W., Koli, J. K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
19. Dubin, P. J. & Kolls, J. K. Th17 cytokines and mucosal immunity. Immunol. Rev. 226, 160-171 (2008).
20. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of iL-17 and iL-22. J. Exp. Med. 206, 35-41 (2009).
21. Oukka, M. Th17 cells in immunity and autoimmunity. Ann. Rheum. Dis. 67 (Suppl. 3), 26-29 (2008).
22. Acosta-rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & sallusto, F. interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007).
23. Wilson, N. J. et al. Development, cytokine profile and function of human interleukin-17-producing helper T cells. Nat. Immunol. 8, 950-957 (2007).
24. Evans, H. G., suddason, T., Jackson, I., Taams, L. S. & Lord, G. M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl Acad. Sci. USA 104, 17034-17039 (2007).
25. Van Beelen, A. J. et al. stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27, 660-669 (2007).
26. Manel, N., Unutmaz, D. & Littman, D. R. The differentiation of human Th17 cells requires transforming growth factor-β and induction of the nuclear receptor rOrγt. Nat. Immunol. 9, 641-649 (2008).
27. Volpe, E. et al. A critical function for transforming growth factor-β, interleukin-23 and proinflammatory cytokines in driving and modulating human Th17 responses. Nat. Immunol. 9, 650-957 (2008).
28. H17 cells. Nature 454, 350-352 (2008).
29. + T cell precursor. J. Exp. Med. 205, 1903-1916 (2008).
30. De Beaucoudrey, L. et al. Mutations in STAT3 and IL12RB1 impair the development of human iL-17-producing T cells. J. Exp. Med. 205, 1543-1550 (2008).
31. Ma, C. S. et al. Deficiency of Th17 cells in hyper ige syndrome due to mutations in sTAT3. J. Exp. Med. 205, 1551-1557 (2008).
32. Milner, J. D. et al. impaired Th17 differentiation in subjects with autosomal dominant hyper-ige syndrome. Nature 452, 773-776 (2008).
33. Santarlasci, V. et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur. J. Immunol. 39, 207-215 (2009).
34. Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. & segal, B. M. iL-12- and iL-23-modulated T cells induce distinct types of eAe based on histology, CNs chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535-1541 (2009).
35. Doodes, P. D. et al. Development of proteoglycaninduced arthritis is independent of iL-17. J. Immunol. 181, 329-337 (2008).
36. Luger, D. et al. either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799-810 (2008).
37. Collison, L. W. & vignali, D. A. interleukin-35: odd one out or part of the family? Immunol. Rev. 226, 248-262 (2008).
38. Komiyama, Y. et al. iL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566-573 (2006).
39. Nakae, S., Nambu, A., sudo, K. & iwakura, Y. suppression of immune induction of collageninduced arthritis in iL-17-deficient mice. J. Immunol. 171, 6173-6177 (2003).
40. Hofstetter, H. H. et al. Therapeutic efficacy of iL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 237, 123-130 (2005).
41. Ogawa, A., Andoh, A., Araki, Y., Bamba, T. & Fujiyama, Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110, 55-62 (2004).
42. Zhang, Z. et al. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int. Immunopharmacol. 7, 409-416 (2007).
43. Duerr, R. H. et al. A genome-wide association study identifies iL23r as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
44. Fuss, I. J. et al. Both iL-12p70 and iL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-iL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9-15 (2006).
45. Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861 (2007).
46. Lee, Y. K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 (2009).
47. Shi, G. et al. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J. Immunol. 181, 7205-7213 (2008).
48. Bending, D. et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/sCiD recipient mice. J. Clin. Invest. [doi:10.1172/JCi37865] (2009).
49. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGFbeta. J. Immunol. 178, 6725-6729 (2007).
50. Koenen, H. J. et al. Human CD25highFoxp3pos regulatory T cells differentiate into iL-17-producing cells. Blood 112, 2340-2352 (2008).
51. Beriou, G. et al. iL-17 producing human peripheral regulatory T cells retain suppressive function. Blood [doi:10.1182/blood-2008-10-183251] (2009).
52. Nakae, S. et al. iL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in iL-1 receptor antagonist. Proc. Natl Acad. Sci. USA 100, 5986-5990 (2003).
53. + Th cells that cause autoimmune arthritis. J. Exp. Med. 204, 41-47 (2007).
54. Fujimoto, M. et al. interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58, 3710-3719 (2008).
55. Young, D. A. et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56, 1152-1163 (2007).
56. Mathur, A. N. et al. sTAT3 and sTAT4 direct development of iL-17-secreting Th cells. J. Immunol. 178, 4901-4907 (2007).
57. Hildner, K. M. et al. Targeting of the transcription factor sTAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. J. Immunol. 178, 3427-3436 (2007).
58. Geboes, L. et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 60, 390-395 (2009).
59. Zheng, Y. et al. interleukin-22, a TH17 cytokine, mediates iL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651 (2007).
60. Piskin, G., sylva-steenland, R. M., Bos, J. D. & Teunissen, M. B. In vitro and in situ expression of iL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176, 1908-1915 (2006).
61. Capon, F. et al. sequence variants in the genes for the interleukin-23 receptor (iL23r) and its ligand (iL12B) confer protection against psoriasis. Hum. Genet. 122, 201-206 (2007).
62. Nair, R. P. et al. Polymorphisms of the iL12B and iL23r genes are associated with psoriasis. J. Invest. Dermatol. 128, 1653-1661 (2008).
63. Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183-3194 (2007).
64. Arican, O., sasmaz, S. & Ciragil, P. serum levels of TNF-alpha, iFN-gamma, iL-6, iL-8, iL-12, iL-17, and iL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 5, 273-279 (2005).
65. Leonardi, C. L. et al. efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOeNiX 1). Lancet 371, 1665-1674 (2008).
66. Papp, K. A. et al. efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOeNiX 2). Lancet 371, 1675-1684 (2008).
67. Fossiez, F. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593-2603 (1996).
68. Sato, K. et al. regulation of osteoclast differentiation and function by the CaMK-CreB pathway. Nat. Med. 12, 1410-1416 (2006).
69. Kirkham, B. W. et al. synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGe study cohort). Arthritis Rheum. 54, 1122-1131 (2006).
70. Bush, K. A., Farmer, K. M., walker, J. S. & Kirkham, B. W. reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor igG1 Fc fusion protein. Arthritis Rheum. 46, 802-805 (2002).
71. Lubberts, E. iL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41, 84-91 (2008).
72. Aarvak, T., Chabaud, M., Miossec, P. & Natvig, J. B. iL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 162, 1246-1251 (1999).
73. Mauritz, N. et al. Treatment with γ-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum. 31, 1297-1304 (1988).
74. Cooper, S. M., sriram, S. & ranges, G. E. suppression of murine collagen-induced arthritis with monoclonal anti-ia antibodies and augmentation with iFN-gamma. J. Immunol. 141, 1958-1962 (1988).
75. Singh, R., Aggarwal, A. & Misra, R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J. Rheumatol. 34, 2285-2290 (2007).
76. Notley, C. A. et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205, 2491-2497 (2008).
77. Martin-Orozco, N., Chung, Y., Chang, S. H., wang, Y. H. & Dong, C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39, 216-224 (2009).